Search

Your search keyword '"Ennishi, Daisuke"' showing total 583 results
Start Over Author "Ennishi, Daisuke"
583 results on '"Ennishi, Daisuke"'

151. Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis

Author

Ying, Hsia-Yuan, primary, Jiang, Yanwen, additional, Ortega-Molina, Ana, additional, Geng, Huimin, additional, McNally, Dylan, additional, Wang, Ling, additional, Doane, Ashley, additional, Agirre, Xabier, additional, Ju, Haiying, additional, Poloway, David, additional, Teater, Matt, additional, Parsa, Sara, additional, Ennishi, Daisuke, additional, Scott, David W, additional, Shaknovich, Rita, additional, Gascoyne, Randy D., additional, Tam, Wayne, additional, Elemento, Olivier, additional, Wendel, Hans-Guido, additional, and Melnick, Ari, additional

Published
2016
Full Text
View/download PDF

152. Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma

Author

Chan, Fong Chun, primary, Kridel, Robert, additional, Mottok, Anja, additional, Boyle, Merrill, additional, Farinha, Pedro, additional, Tan, King, additional, Meissner, Barbara, additional, Bashashati, Ali, additional, McPherson, Andrew, additional, Roth, Andrew, additional, Shumansky, Karey, additional, Yap, Damian, additional, Ben-Neriah, Susana, additional, Rosner, Jamie, additional, Smith, Maia A., additional, Nielsen, Cydney, additional, Telenius, Adele, additional, Ennishi, Daisuke, additional, Mungall, Andrew J., additional, Moore, Richard, additional, Morin, Ryan D., additional, Johnson, Nathalie A., additional, Sehn, Laurie H, additional, Connors, Joseph M., additional, Scott, David W, additional, Steidl, Christian, additional, Marra, Marco A., additional, Gascoyne, Randy D, additional, and Shah, Sohrab P., additional

Published
2016
Full Text
View/download PDF

153. Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma

Author

Kridel, Robert, primary, Chan, Fong Chun, additional, Mottok, Anja, additional, Boyle, Merrill, additional, Farinha, Pedro, additional, Tan, King, additional, Meissner, Barbara, additional, Bashashati, Ali, additional, Ben-Neriah, Susana, additional, Gine, Eva, additional, Ennishi, Daisuke, additional, Mungall, Andrew J., additional, Morin, Ryan D., additional, Johnson, Nathalie A., additional, Sehn, Laurie H., additional, Tousseyn, Thomas, additional, Dogan, Ahmet, additional, Connors, Joseph M., additional, Scott, David W., additional, Steidl, Christian, additional, Marra, Marco A., additional, Gascoyne, Randy D., additional, and Shah, Sohrab P., additional

Published
2016
Full Text
View/download PDF

154. Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

Author

Ennishi, Daisuke, primary, Bashashati, Ali, additional, Saberi, Saeed, additional, Mottok, Anja, additional, Meissner, Barbara, additional, Boyle, Merrill, additional, Ben-Neriah, Susana, additional, Kridel, Robert, additional, Dominguez-Sola, David, additional, Savage, Kerry J, additional, Sehn, Laurie H, additional, Connors, Joseph M., additional, Morin, Ryan D., additional, Marra, Marco A., additional, Shah, Sohrab P., additional, Steidl, Christian, additional, Scott, David W., additional, and Gascoyne, Randy D, additional

Published
2016
Full Text
View/download PDF

155. TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Author

Ennishi, Daisuke, Healy, Shannon, Bashashati, Ali, Saberi, Saeed, Hother, Christoffer, Mottok, Anja, Chan, Fong Chun, Chong, Lauren, Abraham, Libin, Kridel, Robert, Boyle, Merrill, Meissner, Barbara, Aoki, Tomohiro, Takata, Katsuyoshi, Woolcock, Bruce W., Viganò, Elena, Gold, Michael, Molday, Laurie L., Molday, Robert S., Telenius, Adele, Li, Michael Y., Wretham, Nicole, Dos Santos, Nancy, Wong, Mark, Viller, Natasja N., Uger, Robert A., Duns, Gerben, Baticados, Abigail, Madero, Angel, Bristow, Brianna N., Farinha, Pedro, Slack, Graham W., Ben-Neriah, Susana, Lai, Daniel, Zhang, Allen W., Salehi, Sohrab, Shulha, Hennady P., Chiu, Derek S., Mostafavi, Sara, Gerrie, Alina S., Huang, Da Wei, Rushton, Christopher, Villa, Diego, Sehn, Laurie H., Savage, Kerry J., Mungall, Andrew J., Weng, Andrew P., Bally, Marcel B., Morin, Ryan D., Cohen Freue, Gabriela V., Staudt, Louis M., Connors, Joseph M., Marra, Marco A., Shah, Sohrab P., Gascoyne, Randy D., Scott, David W., and Steidl, Christian

Abstract

Transmembrane protein 30A (TMEM30A) maintains the asymmetric distribution of phosphatidylserine, an integral component of the cell membrane and ‘eat-me’ signal recognized by macrophages. Integrative genomic and transcriptomic analysis of diffuse large B-cell lymphoma (DLBCL) from the British Columbia population-based registry uncovered recurrent biallelic TMEM30Aloss-of-function mutations, which were associated with a favorable outcome and uniquely observed in DLBCL. Using TMEM30A-knockout systems, increased accumulation of chemotherapy drugs was observed in TMEM30A-knockout cell lines and TMEM30A-mutated primary cells, explaining the improved treatment outcome. Furthermore, we found increased tumor-associated macrophages and an enhanced effect of anti-CD47 blockade limiting tumor growth in TMEM30A-knockout models. By contrast, we show that TMEM30A loss-of-function increases B-cell signaling following antigen stimulation—a mechanism conferring selective advantage during B-cell lymphoma development. Our data highlight a multifaceted role for TMEM30A in B-cell lymphomagenesis, and characterize intrinsic and extrinsic vulnerabilities of cancer cells that can be therapeutically exploited.

Published
2020
Full Text
View/download PDF

156. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

Author

Boice, Michael, primary, Salloum, Darin, additional, Mourcin, Frederic, additional, Sanghvi, Viraj, additional, Amin, Rada, additional, Oricchio, Elisa, additional, Jiang, Man, additional, Mottok, Anja, additional, Denis-Lagache, Nicolas, additional, Ciriello, Giovanni, additional, Tam, Wayne, additional, Teruya-Feldstein, Julie, additional, de Stanchina, Elisa, additional, Chan, Wing C., additional, Malek, Sami N., additional, Ennishi, Daisuke, additional, Brentjens, Renier J., additional, Gascoyne, Randy D., additional, Cogné, Michel, additional, Tarte, Karin, additional, and Wendel, Hans-Guido, additional

Published
2016
Full Text
View/download PDF

157. Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma

Author

Ortega-Molina, Ana, primary, Boss, Isaac W., additional, Canela, Andres, additional, Pan, Heng, additional, Jiang, Yanwen, additional, Zhao, Chunying, additional, Jiang, Man, additional, Hu, Deqing, additional, Lee, Ji-Eun, additional, Chen, Hua-Tang, additional, Ennishi, Daisuke, additional, Scott, David W., additional, Hother, Christoffer, additional, Liu, Shichong, additional, Cao, Xing-Jun, additional, Tam, Wayne, additional, Shaknovich, Rita, additional, Garcia, Benjamin A., additional, Gascoyne, Randy D., additional, Ge, Kai, additional, Shilatifard, Ali, additional, Elemento, Olivier, additional, Nussenzweig, Andre, additional, Melnick, Ari M., additional, and Wendel, Hans-Guido, additional

Published
2016
Full Text
View/download PDF

158. Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma

Author

Kusakabe, Manabu, primary, Wang, Xuehai, additional, Simkin, Guillermo, additional, Meskas, Justin, additional, Zhang, Chaoran, additional, Ennishi, Daisuke, additional, Kridel, Robert, additional, Boyle, Merrill, additional, Chavez, Elizabeth, additional, Hung, Stacy, additional, Scott, David W, additional, Steidl, Christian, additional, Gascoyne, Randy D., additional, Brinkman, Ryan R., additional, and Weng, Andrew P, additional

Published
2015
Full Text
View/download PDF

159. Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype

Author

Ennishi, Daisuke, primary, Mottok, Anja, additional, Savage, Kerry J., additional, Ben-Neriah, Susana, additional, Shulha, Hennady, additional, Farinha, Pedro, additional, Chan, Fong Chun, additional, Meissner, Barbara, additional, Boyle, Merrill, additional, Hother, Christoffer E, additional, Kridel, Robert, additional, Morin, Ryan, additional, Marra, Marco A, additional, Sehn, Laurie H., additional, Steidl, Christian, additional, Connors, Joseph M., additional, Scott, David W, additional, and Gascoyne, Randy D., additional

Published
2015
Full Text
View/download PDF

160. Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma

Author

Ennishi, Daisuke, primary, Mottok, Anja, additional, Shulha, Hennady, additional, Farinha, Pedro, additional, Chan, Fong Chun, additional, Meissner, Barbara, additional, Boyle, Merrill, additional, Ben-Neriah, Susana, additional, Hother, Christoffer E, additional, Kridel, Robert, additional, Morin, Ryan, additional, Marra, Marco A, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Connors, Joseph M., additional, Steidl, Christian, additional, Scott, David W, additional, and Gascoyne, Randy D., additional

Published
2015
Full Text
View/download PDF

161. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Author

Dominguez, Pilar M., Melnick, Ari, Shaknovich, Rita, Teater, Matt, Ghione, Paola, Redmond, David, Elemento, Olivier, Zhengming Chen, Ennishi, Daisuke, Scott, David W., Cimmino, Luisa, Aifantis, Iannis, Chaudhuri, Jayanta, Gascoyne, Randy D., and Inghirami, Giorgio

Subjects
CYTIDINE deaminase, EPIGENETICS, HETEROGENEITY, GERMINAL centers, DIFFUSE large B-cell lymphomas
Abstract

Epigenetic heterogeneity is emerging as a feature of tumors. In diffuse large B-cell lymphoma (DLBCL), increased cytosine methylation heterogeneity is associated with poor clinical outcome, yet the underlying mechanisms remain unclear. Activation-induced cytidine deaminase (AICDA), an enzyme that mediates affinity maturation and facilitates DNA demethylation in germinal center (GC) B cells, is required for DLBCL pathogenesis and linked to inferior outcome. Here we show that AICDA overexpression causes more aggressive disease in BCL2-driven murine lymphomas. This phenotype is associated with increased cytosine methylation heterogeneity, but not with increased AICDA-mediated somatic mutation burden. Reciprocally, the cytosine methylation heterogeneity characteristic of normal GC B cells is lost upon AICDA depletion. These observations are relevant to human patients, since DLBCLs with high AICDA expression manifest increased methylation heterogeneity vs. AICDA-low DLBCLs. Our results identify AICDA as a driver of epigenetic heterogeneity in Bcell lymphomas with potential significance for other tumors with aberrant expression of cytidine deaminases. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

163. Identification of Recurrent Non-Coding Driver Mutations in Non-Hodgkin Lymphomas through Integrative Genomic Analysis of 777 Patients

Author

Jiang, Aixiang, Grande, Bruno M., Arthur, Sarah E, Alcaide, Miguel, Ennishi, Daisuke, Jessa, Selin, Pararajalingam, Prasath, Meissner, Barbara, Boyle, Merrill, Chong, Lauren, Lai, Daniel, Davidson, Jordan, Mottok, Anja, Bushell, Kevin R, Sehn, Laurie H., Farinha, Pedro, Shah, Sohrab P, Mungall, Andrew J., Gascoyne, Randy D., Marra, Marco A, Steidl, Christian, Connors, Joseph M, Scott, David W., and Morin, Ryan D.

Published
2017
Full Text
View/download PDF

164. Genetic Characterization and Clinical Impact of Loss of MHC Class I and II Expression in De Novo Diffuse Large B-Cell Lymphoma

Author

Ennishi, Daisuke, Mottok, Anja, Farinha, Pedro, Chan, Fong Chun, Bashashati, Ali, Saberi, Saeed, Meissner, Barbara, Boyle, Merrill, Ben-Neriah, Susana, Kridel, Robert, Savage, Kerry J, Sehn, Laurie H., Morin, Ryan D., Marra, Marco A, Shah, Sohrab P, Connors, Joseph M, Gascoyne, Randy D., Scott, David W., and Steidl, Christian

Published
2017
Full Text
View/download PDF

165. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies

Author

Scott, David W., primary, Mottok, Anja, additional, Ennishi, Daisuke, additional, Wright, George W., additional, Farinha, Pedro, additional, Ben-Neriah, Susana, additional, Kridel, Robert, additional, Barry, Garrett S., additional, Hother, Christoffer, additional, Abrisqueta, Pau, additional, Boyle, Merrill, additional, Meissner, Barbara, additional, Telenius, Adele, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Slack, Graham W., additional, Steidl, Christian, additional, Staudt, Louis M., additional, Connors, Joseph M., additional, Rimsza, Lisa M., additional, and Gascoyne, Randy D., additional

Published
2015
Full Text
View/download PDF

166. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients

Author

Lim, Emilia L, primary, Trinh, Diane L, additional, Scott, David W, additional, Chu, Andy, additional, Krzywinski, Martin, additional, Zhao, Yongjun, additional, Robertson, A Gordon, additional, Mungall, Andrew J, additional, Schein, Jacqueline, additional, Boyle, Merrill, additional, Mottok, Anja, additional, Ennishi, Daisuke, additional, Johnson, Nathalie A, additional, Steidl, Christian, additional, Connors, Joseph M, additional, Morin, Ryan D, additional, Gascoyne, Randy D, additional, and Marra, Marco A, additional

Published
2015
Full Text
View/download PDF

167. Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab

Author

Ikegawa, Shuntaro, Meguri, Yusuke, Mizuhara, Kentaro, Fukumi, Takuya, Kobayashi, Hiroki, Sumii, Yuichi, Kondo, Takumi, Sando, Yasuhisa, Iwamoto, Miki, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Fujii, Keiko, Fujii, Nobuharu, Fujisawa, Yuka, Imai, Toshi, Maeda, Yoshinobu, and Matsuoka, Ken-ichi

Published
2021
Full Text
View/download PDF

168. The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Savage, Kerry J., primary, Sehn, Laurie H., additional, Villa, Diego, additional, Kansara, Roopesh R., additional, Mottok, Anja, additional, Ennishi, Daisuke, additional, Ben-Neriah, Susana, additional, Kridel, Robert, additional, Steidl, Christian, additional, Tan, King L., additional, Johnson, Nathalie, additional, Slack, Graham W., additional, Connors, Joseph M., additional, Farinha, Pedro, additional, Scott, David W., additional, and Gascoyne, Randy D., additional

Published
2014
Full Text
View/download PDF

169. Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma

Author

Ennishi, Daisuke, primary, Hoffer, Christoffer, additional, Shulha, Hennady, additional, Mottok, Anja, additional, Farinha, Pedro, additional, Chan, Fong Chun, additional, Meissner, Barbara, additional, Boyle, Merrill, additional, Ben-Neriah, Susana, additional, Morin, Ryan D, additional, Marra, Marco A., additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Connors, Joseph M, additional, Steidl, Christian, additional, Scott, David W., additional, and Gascoyne, Randy D., additional

Published
2014
Full Text
View/download PDF

171. Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry

Author

Scott, David W., primary, Mottok, Anja, additional, Ennishi, Daisuke, additional, Wright, George W., additional, Farinha, Pedro, additional, Ben-Neriah, Susana, additional, Kridel, Robert, additional, Barry, Garrett S, additional, Hother, Christoffer E, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Staudt, Louis M., additional, Connors, Joseph M., additional, Rimsza, Lisa M., additional, and Gascoyne, Randy D., additional

Published
2014
Full Text
View/download PDF

173. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin--specific clinical impact.

Author

Ennishi, Daisuke, Mottok, Anja, Ben-Neriah, Susana, Shulha, Hennady P., Farinha, Pedro, Fong Chun Chan, Meissner, Barbara, Boyle, Merrill, Hother, Christoffer, Kridel, Robert, Lai, Daniel, Saberi, Saeed, Bashashati, Ali, Shah, Sohrab P., Morin, Ryan D., Marra, Marco A., Savage, Kerry J., Sehn, Laurie H., Steidl, Christian, and Connors, Joseph M.

Subjects
*VINCRISTINE, *B cells, *DOXORUBICIN, *ANTHRACYCLINES, *RITUXIMAB, *ANTINEOPLASTIC agents
Abstract

The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated using high-resolution genetic assays. In this study, we profiled MYC and BCL2 genetic alterations using next-generation sequencing and high-resolution SNP array in 347 de novo DLBCL cases treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Cancer Agency Cell-of- origin (COO) subtype was determined by Lymph2Cx digital gene expression profiling. We showed that the incidence o fMYC/BCL2 genetic alterations and their clinical significance were largely dependent on COO subtypes. It is noteworthy that the presence of BCL2 gain/amplification is significantly associated with poor outcome in activated B-cell-like and BCL2 translocation with poor outcome in germinal center B-cell subtypes, respectively. Both have prognostic significance independent of MYC/BCL2 dual expression and the International Prognostic Index (IPI). Furthermore, the combination of BCL2 genetic alterations with IPI identifies markedly worse prognostic groups within individual COO subtypes. Thus, high-resolution genomic assays identify extremely poor prognostic groups within each COO subtype on the basis of BCL2 genetic status in this large, uniformly R-CHOP-treated population-based cohort of DLBCL. These results suggest COO subtype-specific biomarkers based on BCL2 genetic alterations can be used to risk-stratify patients with DLBCL treated with immunochemotherapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

174. High-resolution architecture and partner genes of MYCrearrangements in lymphoma with DLBCL morphology

Author

Chong, Lauren C., Ben-Neriah, Susana, Slack, Graham W., Freeman, Ciara, Ennishi, Daisuke, Mottok, Anja, Collinge, Brett, Abrisqueta, Pau, Farinha, Pedro, Boyle, Merrill, Meissner, Barbara, Kridel, Robert, Gerrie, Alina S., Villa, Diego, Savage, Kerry J., Sehn, Laurie H., Siebert, Reiner, Morin, Ryan D., Gascoyne, Randy D., Marra, Marco A., Connors, Joseph M., Mungall, Andrew J., Steidl, Christian, and Scott, David W.

Abstract

Genomic rearrangements in the MYClocus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYCrearrangements have primarily used fluorescence in situ hybridization (FISH) assays to characterize break-apart status but have rarely examined breakpoint location, and in some cases have not examined partner identity. We performed targeted sequencing of MYC, BCL2, BCL6, and the immunoglobulin (IG) loci in 112 tumors with DLBCL morphology harboring MYCrearrangement. We characterized the location of the MYCrearrangement at base pair resolution and identified the partner in 88 cases. We observed a cluster of breakpoints upstream of the MYCcoding region and in intron 1 (the “genic cluster”). Genic cluster rearrangements were enriched for translocations involving IGH(80%), whereas nongenic rearrangements occurred mostly downstream of the MYCgene with a variety of partners, including IGLand IGK. Other recurrent partners included BCL6, ZCCHC7, and RFTN1, which has not previously been described as a MYCpartner. We compared 2 commercially available FISH break-apart assays for the MYClocus and observed discordant results in 32% of cases examined, including some with MYC-IGLand MYC-IGKrearrangements. In cases of high-grade B-cell lymphoma with MYCand BCL2and/or BCL6rearrangement (HGBL-DH), so-called “double-hit” lymphomas, the majority of MYCrearrangements had non-IGpartners (65%), with breakpoints outside the genic cluster (72%). In patients with de novo HGBL-DH of DLBCL morphology, MYC-IGrearrangements showed a trend toward inferior time to progression and overall survival compared with MYC–non-IGrearrangements. Our data reveal clinically relevant architecture of MYCrearrangements in lymphomas with DLBCL morphology.

Published
2018
Full Text
View/download PDF

175. High-grade B-cell lymphoma with MYCand BCL2and/or BCL6rearrangements with diffuse large B-cell lymphoma morphology

Author

Scott, David W., King, Rebecca L., Staiger, Annette M., Ben-Neriah, Susana, Jiang, Aixiang, Horn, Heike, Mottok, Anja, Farinha, Pedro, Slack, Graham W., Ennishi, Daisuke, Schmitz, Norbert, Pfreundschuh, Michael, Nowakowski, Grzegorz S., Kahl, Brad S., Connors, Joseph M., Gascoyne, Randy D., Ott, German, Macon, William R., and Rosenwald, Andreas

Abstract

High-grade B-cell lymphoma with MYCand BCL2and/or BCL6rearrangements (HGBL-DH/TH) is a newly defined entity in the latest World Health Organization Classification. Accurate diagnosis would appear to mandate fluorescence in situ hybridization (FISH) for all tumors with diffuse large B-cell lymphoma (DLBCL) morphology. We present the results of FISH, cell-of-origin, and immunohistochemistry (IHC) testing from 1228 DLBCL biopsies from 3 clinical trials and a population-based registry. HGBL-DH/TH made up 7.9% of the DLBCL, confined primarily to the germinal center B-cell–like (GCB; 13.3%) compared with activated B-cell-like (ABC; 1.7%) subtype (P< .001). HGBL-DH/TH with BCL2rearrangement is a GCB phenomenon with no cases observed in 415 ABC DLBCL. A screening strategy restricting FISH testing to tumors of GCB subtype (by Lymph2Cx or Hans IHC) plus dual protein expression of MYC and BCL2 by IHC could limit testing to 11% to 14% of tumors, with a positive predictive value of 30% to 37%; however, this strategy would miss approximately one-quarter of tumors with HBGL-DH/TH with BCL2rearrangement and one-third of all HGBL-DH/TH. These results provide accurate estimation of the proportion of HGBL-DH/TH among tumors with DLBCL morphology and allow determination of the impact of various methods available to screen DLBCL tumors for FISH testing.

Published
2018
Full Text
View/download PDF

176. Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival

Author

Ennishi, Daisuke, primary, Chan, Fong Chun, additional, Scott, David W., additional, Hother, Christoffer, additional, Meissner, Barbara, additional, Boyle, Merrill, additional, Morin, Ryan D, additional, Sehn, Laurie H., additional, Marra, Marco A., additional, Connors, Joseph M., additional, Steidl, Christian, additional, and Gascoyne, Randy D., additional

Published
2013
Full Text
View/download PDF

177. Germinal Center B-Cell-Like versus Non-Germinal Center B-Cell-Like as Important Prognostic Factor for Localized Nodal DLBCL

Author

Habara, Toshiyuki, primary, Sato, Yasuharu, additional, Takata, Katsuyoshi, additional, Iwaki, Noriko, additional, Okumura, Hirokazu, additional, Sonobe, Hiroshi, additional, Tanaka, Takehiro, additional, Orita, Yorihisa, additional, Al-Kader, Lamia Abd, additional, Asano, Naoko, additional, Ennishi, Daisuke, additional, and Yoshino, Tadashi, additional

Published
2012
Full Text
View/download PDF

178. Genetic profiling of MYCand BCL2in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact

Author

Ennishi, Daisuke, Mottok, Anja, Ben-Neriah, Susana, Shulha, Hennady P., Farinha, Pedro, Chan, Fong Chun, Meissner, Barbara, Boyle, Merrill, Hother, Christoffer, Kridel, Robert, Lai, Daniel, Saberi, Saeed, Bashashati, Ali, Shah, Sohrab P., Morin, Ryan D., Marra, Marco A., Savage, Kerry J., Sehn, Laurie H., Steidl, Christian, Connors, Joseph M., Gascoyne, Randy D., and Scott, David W.

Abstract

The clinical significance of MYCand BCL2genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated using high-resolution genetic assays. In this study, we profiled MYCand BCL2genetic alterations using next-generation sequencing and high-resolution SNP array in 347 de novo DLBCL cases treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Cancer Agency. Cell-of-origin (COO) subtype was determined by Lymph2Cx digital gene expression profiling. We showed that the incidence of MYC/BCL2genetic alterations and their clinical significance were largely dependent on COO subtypes. It is noteworthy that the presence of BCL2gain/amplification is significantly associated with poor outcome in activated B-cell-like and BCL2translocation with poor outcome in germinal center B-cell subtypes, respectively. Both have prognostic significance independent of MYC/BCL2 dual expression and the International Prognostic Index (IPI). Furthermore, the combination of BCL2genetic alterations with IPI identifies markedly worse prognostic groups within individual COO subtypes. Thus, high-resolution genomic assays identify extremely poor prognostic groups within each COO subtype on the basis of BCL2genetic status in this large, uniformly R-CHOP-treated population-based cohort of DLBCL. These results suggest COO subtype-specific biomarkers based on BCL2genetic alterations can be used to risk-stratify patients with DLBCL treated with immunochemotherapy.

Published
2017
Full Text
View/download PDF

184. The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.

Author

Ennishi, Daisuke, primary, Maeda, Yoshinobu, additional, Niitsu, Nozomi, additional, Kojima, Minoru, additional, Izutsu, Koji, additional, Takizawa, Jun, additional, Kusumoto, Shigeru, additional, Okamoto, Masataka, additional, Yokoyama, Masahiro, additional, Takamatsu, Yasushi, additional, Sunami, Kazutaka, additional, Miyata, Akira, additional, Murayama, Kayoko, additional, Sakai, Akira, additional, Matsumoto, Morio, additional, Shinagawa, Katsuji, additional, Takaki, Akinobu, additional, Matsuo, Keitaro, additional, Kinoshita, Tomohiro, additional, and Tanimoto, Mitsune, additional

Published
2009
Full Text
View/download PDF

185. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

Author

Mishima, Yuji, primary, Sugimura, Natsuhiko, additional, Matsumoto-Mishima, Yuko, additional, Terui, Yasuhito, additional, Takeuchi, Kengo, additional, Asai, Suzuka, additional, Ennishi, Daisuke, additional, Asai, Hiroaki, additional, Yokoyama, Masahiro, additional, Kojima, Kiyotsugu, additional, and Hatake, Kiyohiko, additional

Published
2009
Full Text
View/download PDF

188. Addition of Rituximab to CHOP Chemotherapy Does Not Improve Clinical Outcome in Patients with Localized Gastric Diffuse Large B-Cell Lymphoma: A Retrospective Study by Ganken Adult Lymphoma Study Group (Single Institute Analysis).

Author

Yokoyama, Masahiro, primary, Ennishi, Daisuke, additional, Asai, Hiroaki, additional, Ueda, Kyoko, additional, Kodaira, Makoto, additional, Yamada, Shuhei, additional, Myojo, Tomohiro, additional, Mishima, Yuko, additional, Sakajiri, Sakura, additional, Takeuchi, Kengo, additional, Saotome, Takashi, additional, Terui, Yasuhito, additional, Takahashi, Shunji, additional, Ito, Yoshinori, additional, and Hatake, Kiyohiko, additional

Published
2007
Full Text
View/download PDF

192. Addition of Rituximab to CHOP Regimen Improves Clinical Outcome in Non-Germinal Center Type Diffuse Large B-Cell Lymphoma.

Author

Yokoyama, Masahiro, primary, Ennishi, Daisuke, additional, Ueda, Kyoko, additional, Kodaira, Makoto, additional, Yamada, Shuhei, additional, Myojo, Tomohiro, additional, Sakajiri, Sakura, additional, Mishima, Yuko, additional, Takeuchi, Kengo, additional, Saotome, Takashi, additional, Terui, Yasuhito, additional, Takahashi, Shunji, additional, Ito, Yoshinori, additional, and Hatake, Kiyohiko, additional

Published
2006
Full Text
View/download PDF

194. Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory B-cell lymphoma who received tisagenlecleucel

Author

Terao, Toshiki, Kitamura, Wataru, Fujii, Nobuharu, Asada, Noboru, Kamoi, Chihiro, Fujiwara, Kanako, Kondo, Kaho, Matsubara, Chisato, Hayashino, Kenta, Seike, Keisuke, Fujiwara, Hideaki, Ennishi, Daisuke, Nishimori, Hisakazu, Fujii, Keiko, Matsuoka, Ken-ichi, and Maeda, Yoshinobu

Abstract

•Corticosteroid administration is used for CRS/ICANS in patients with tisa-cel.•Excessive corticosteroid use is an independent poor prognostic factor.•This poor prognostic impact remains only in SD/PD patients, but not CR/PR patients.•Early elevation of regulatory T-cells after tisa-cel suppresses CRS onset.•Elevation of CD4+central memory T-cells is a favorable prognostic factor.

Published
2023
Full Text
View/download PDF

195. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

Author

Savage, Kerry J., Slack, Graham W., Mottok, Anja, Sehn, Laurie H., Villa, Diego, Kansara, Roopesh, Kridel, Robert, Steidl, Christian, Ennishi, Daisuke, Tan, King L., Ben-Neriah, Susana, Johnson, Nathalie A., Connors, Joseph M., Farinha, Pedro, Scott, David W., and Gascoyne, Randy D.

Abstract

Dual expression of MYC and BCL2 by immunohistochemistry (IHC) is associated with poor outcome in diffuse large B-cell lymphoma (DLBCL). Dual translocation of MYC and BCL2, so-called “double-hit lymphoma,” has been associated with a high risk of central nervous system (CNS) relapse; however, the impact of dual expression of MYC and BCL2 (dual expressers) on the risk of CNS relapse remains unknown. Pretreatment formalin-fixed paraffin-embedded DLBCL biopsies derived from patients subsequently treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were assembled on tissue microarrays from 2 studies and were evaluated for expression of MYC and BCL2 by IHC. In addition, cell of origin was determined by IHC and the Lymph2Cx gene expression assay in a subset of patients. We identified 428 patients who met the inclusion criteria. By the recently described CNS risk score (CNS–International Prognostic Index [CNS-IPI]), 34% were low risk (0 to 1), 45% were intermediate risk (2 to 3), and 21% were high risk (4 or greater). With a median follow-up of 6.8 years, the risk of CNS relapse was higher in dual expressers compared with non-dual expressers (2-year risk, 9.7% vs 2.2%; P = .001). Patients with activated B-cell or non–germinal center B-cell type DLBCL also had an increased risk of CNS relapse. However, in multivariate analysis, only dual expresser status and CNS-IPI were associated with CNS relapse. Dual expresser MYC+ BCL2+ DLBCL defines a group at high risk of CNS relapse, independent of CNS-IPI score and cell of origin. Dual expresser status may help to identify a high-risk group who should undergo CNS-directed evaluation and consideration of prophylactic strategies.

Published
2016
Full Text
View/download PDF

196. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy.

Author

Iwamuro, Masaya, Tanaka, Takehiro, Ennishi, Daisuke, Matsueda, Kazuhiro, Yoshioka, Masao, Miyahara, Koji, Sakaguchi, Chihiro, Nishimura, Mamoru, Nagahara, Teruya, Mannami, Tomohiko, Takenaka, Ryuta, Oka, Shohei, Inoue, Masafumi, Takimoto, Hidetaka, Inaba, Tomoki, Kobayashi, Sayo, Toyokawa, Tatsuya, Tsugeno, Hirofumi, Suzuki, Seiyuu, and Sawada, Sachiko

Subjects
*FOLLICULAR lymphoma, *INTESTINES, *SURVIVAL rate, *OVERALL survival, *DISEASE progression
Abstract

Patients with primary intestinal follicular lymphoma are often followed-up without a specific treatment, and this approach is called the "watch-and-wait approach." However, the long-term outcomes of this patient group have not been sufficiently investigated. We enrolled patients with primary intestinal follicular lymphoma who were diagnosed before 2016 and managed with the watch-and-wait approach in 20 institutions. We retrospectively investigated the overall, disease-specific, and event-free survival rates as well as the rate of spontaneous regression. Among the 248 patients with follicular lymphoma with gastrointestinal involvement, 124 had localized disease (stage I or II1). We analyzed the data of 73 patients who were managed using the watch-and-wait approach. During the mean follow-up period of 8.3 years, the follicular lymphoma had spontaneously resolved in 16.4% of the patients. The 5-year and 10-year overall survival rates were 92.9% and 87.1%, respectively. With disease progression (n = 7), initiation of therapy (n = 7), and histologic transformation to aggressive lymphoma (n = 0) defined as events, the 5-year and 10-year event-free survival rates were 91.1% and 86.9%, respectively. No patient died of progressive lymphoma. Thus, both 5-year and 10-year disease-specific survival rates were 100%. In conclusion, an indolent long-term clinical course was confirmed in the patients with primary intestinal follicular lymphoma. The watch-and-wait strategy is a reasonable approach for the initial management of these patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

197. Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.

Author

Sunami, Kuniko, Naito, Yoichi, Aimono, Eriko, Amano, Toraji, Ennishi, Daisuke, Kage, Hidenori, Kanai, Masashi, Komine, Keigo, Koyama, Takafumi, Maeda, Takahiro, Morita, Sachi, Sakai, Daisuke, Kohsaka, Shinji, Tsuchihara, Katsuya, and Yoshino, Takayuki

Subjects
CANCER hospitals
Abstract

A correction to this paper has been published: https://doi.org/10.1007/s10147-021-01897-w [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

198. Author Correction: 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy.

Author

Sando, Yasuhisa, Matsuoka, Ken-ichi, Sumii, Yuichi, Kondo, Takumi, Ikegawa, Shuntaro, Sugiura, Hiroyuki, Nakamura, Makoto, Iwamoto, Miki, Meguri, Yusuke, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Fujii, Keiko, Fujii, Nobuharu, Utsunomiya, Atae, Oka, Takashi, and Maeda, Yoshinobu

Subjects
AMINOLEVULINIC acid, PHOTODYNAMIC therapy, T-cell lymphoma
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

199. 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy.

Author

Sando, Yasuhisa, Matsuoka, Ken-ichi, Sumii, Yuichi, Kondo, Takumi, Ikegawa, Shuntaro, Sugiura, Hiroyuki, Nakamura, Makoto, Iwamoto, Miki, Meguri, Yusuke, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Fujii, Keiko, Fujii, Nobuharu, Utsunomiya, Atae, Oka, Takashi, and Maeda, Yoshinobu

Subjects
PHOTODYNAMIC therapy, LEUKEMIA, CELL death, BIOMARKERS, HEMATOLOGY
Abstract

Photodynamic therapy (PDT) is an emerging treatment for various solid cancers. We recently reported that tumor cell lines and patient specimens from adult T cell leukemia/lymphoma (ATL) are susceptible to specific cell death by visible light exposure after a short-term culture with 5-aminolevulinic acid, indicating that extracorporeal photopheresis could eradicate hematological tumor cells circulating in peripheral blood. As a bridge from basic research to clinical trial of PDT for hematological malignancies, we here examined the efficacy of ALA-PDT on various lymphoid malignancies with circulating tumor cells in peripheral blood. We also examined the effects of ALA-PDT on tumor cells before and after conventional chemotherapy. With 16 primary blood samples from 13 patients, we demonstrated that PDT efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute ATL. Importantly, PDT could eradicate acute ATL cells remaining after standard chemotherapy or anti-CCR4 antibody, suggesting that PDT could work together with other conventional therapies in a complementary manner. The responses of PDT on indolent tumor cells were various but were clearly depending on accumulation of protoporphyrin IX, which indicates the possibility of biomarker-guided application of PDT. These findings provide important information for developing novel therapeutic strategy for hematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results